Realm Therapeutics, Inc.

Evelo Bio­sciences is on the hunt for a new CEO, with its found­ing chief Sim­ba Gill switch­ing to the chair­man post to free up time for his new gig at Evelo’s in­cu­ba­tor, Flag­ship Pi­o­neer­ing. Gill will trade in his for­mer Flag­ship ti­tle of ven­ture part­ner with the high­er-up role of ex­ec­u­tive part­ner, af­ter orig­i­nal­ly join­ing in 2015. He’ll serve as CEO of Evelo un­til his suc­ces­sor is cho­sen, and at Flag­ship his pri­or­i­ties will be coun­sel­ing and sup­port­ing the ven­ture firm’s port­fo­lio com­pa­nies. Flag­ship has con­tin­ued to sup­port Evelo through­out the in­flam­ma­to­ry dis­ease biotech’s sev­en-year his­to­ry, in­clud­ing lead­ing a di­rect of­fer­ing ear­li­er this sum­mer, four years af­ter an IPO . Look­ing at lever­ag­ing mi­cro­bials to tar­get in­flam­ma­tion, the biotech’s di­rect of­fer­ing — 54.2 mil­lion shares at a pur­chase price of $1.46 a share — net­ted Evelo $79.2 mil­lion in gross pro­ceeds in May. The of­fer­ing would push de­vel­op­ment for­ward in the form of a Phase II tri­al in atopic der­mati­tis for its lead can­di­date EDP1815 and pre­pare to push that same can­di­date in­to reg­is­tra­tion tri­als in pso­ri­a­sis, the biotech added in an SEC fil­ing. Gill said in a state­ment that he’ll “work with the Board and lead­er­ship team to en­sure a seam­less tran­si­tion.” When he takes over as board chair, Lord Ara Darzi will be­come lead in­de­pen­dent di­rec­tor. The ex­ec­u­tive search firm Spencer Stu­art is lead­ing the CEO hunt. Pri­or to join­ing Evelo, Gill was the CEO and pres­i­dent of mok­sha8 Phar­ma­ceu­ti­cals, a Latin Amer­i­can phar­ma­ceu­ti­cal com­pa­ny fo­cused on cen­tral ner­vous sys­tem dis­or­ders. From 2016 to 2019, Gill al­so served as a di­rec­tor at Realm Ther­a­peu­tics, a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny which works on mak­ing im­munomod­u­la­to­ry ther­a­pies. “Sim­ba has had a re­mark­able ca­reer co-found­ing, build­ing and lead­ing com­pa­nies in dis­rup­tive biotech over more than thir­ty-five years,” said Noubar Afeyan, CEO and founder of Flag­ship Pi­o­neer­ing and co-founder of Evelo. Evelo’s shares $EV­LO rose slight­ly, about 3%, af­ter the open­ing bell Thurs­day.

MALVERN, Pa., & STAFFORD, England--(BUSINESS WIRE)--PuriCore (LSE:PURI), the life sciences company focused on the development and commercialization of its novel, safe antimicrobial technology, today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA), allowing it to market its proprietary Sterilox Endoscopy High-Level Disinfectant System as a medical device in the US. The Sterilox System produces a highly effective and safe high-level disinfectant solution that is indicated for use in reprocessing and disinfecting heat-sensitive medical instruments, including endoscopes, between patient procedures. The Sterilox Endoscopy System is based on existing patented and patent-pending PuriCore technology and products that are currently marketed in Europe (primarily in the UK). It produces principally hypochlorous acid, the natural antimicrobial produced by the human body to fight pathogens, from the electrolysis of a saline solution. Sterilox Solutions are completely non-toxic and are of no risk to patients, healthcare professionals, or the environment. “This is a big step in bringing Sterilox to the US endoscopy market, which is the largest in the world,” said Greg Bosch, PuriCore CEO. "We are now developing our commercialization plan and, upon the completion of post-clearance testing, we anticipate installing our first US beta sites for Sterilox Endoscopy Systems by year end.” About PuriCore PuriCore (London Stock Exchange:PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore’s technology mimics the human body’s production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. PuriCore's technology provides a potential solution in a broad range of markets that depend upon controlling contamination, including food safety, medical device disinfection, wound management, and hospitality. Deploying hypocholous acid solutions as soaks, sprays, mists and in other forms, PuriCore’s technology is designed to limit the spread of infectious disease, including major public health threats of Tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and Legionella. To receive additional information on PuriCore or its Sterilox Endoscopy division, please visit our web site at which does not form part of this press release. Contacts PuriCore Keith A. Goldan, 484-321-2700 or Sage Strategic Marketing Jennifer Guinan, 610-410-8111 Jennifer@sagestrat.com >>> Discuss This Story